Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans.

Lang D, Freudenberger C, Weinz C.

Drug Metab Dispos. 2009 May;37(5):1046-55. doi: 10.1124/dmd.108.025551. Epub 2009 Feb 5.

2.

Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.

Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D.

Drug Metab Dispos. 2009 May;37(5):1056-64. doi: 10.1124/dmd.108.025569. Epub 2009 Feb 5.

3.

Tracheobronchial amyloidosis--bronchoscopic diagnosis and therapy of an uncommon disease: a case report.

Brill AK, Woelke K, Schädlich R, Weinz C, Laier-Groeneveld G.

J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 1):51-5.

4.

Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs.

Weinz C, Buetehorn U, Daehler HP, Kohlsdorfer C, Pleiss U, Sandmann S, Schlemmer KH, Schwarz T, Steinke W.

Xenobiotica. 2005 Sep;35(9):891-910.

PMID:
16308283
5.

Pharmacokinetics of repinotan in healthy and brain injured animals.

Schwarz T, Beckermann B, Buehner K, Mauler F, Schuhmacher J, Seidel D, Steinke W, Weinz C, Zimmerd D.

Biopharm Drug Dispos. 2005 Sep;26(6):259-68.

PMID:
15966026
6.

BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.

Mauler F, Horváth E, De Vry J, Jäger R, Schwarz T, Sandmann S, Weinz C, Heinig R, Böttcher M.

CNS Drug Rev. 2003 Winter;9(4):343-58. Review.

7.

Supplemental Content

Support Center